Xenon Pharmaceuticals (NASDAQ:XENE) Director Gary Patou Sells 1,322 Shares

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Xenon Pharmaceuticals Price Performance

Xenon Pharmaceuticals stock opened at $51.21 on Tuesday. The firm has a market capitalization of $4.95 billion, a P/E ratio of -10.90 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 1-year low of $30.00 and a 1-year high of $63.95. The company’s 50-day moving average is $55.74 and its 200 day moving average is $48.68.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same period in the prior year, the firm posted ($0.83) EPS. Research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Institutional Trading of Xenon Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $33,000. Blue Trust Inc. boosted its holdings in Xenon Pharmaceuticals by 2,560.7% in the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares in the last quarter. Danske Bank A S acquired a new stake in Xenon Pharmaceuticals in the third quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the fourth quarter worth about $43,000. Finally, Aster Capital Management DIFC Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the third quarter worth about $39,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on XENE. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Guggenheim reiterated a “buy” rating and issued a $90.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a research note on Monday, March 9th. Royal Bank Of Canada lifted their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, HC Wainwright increased their price target on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of “Buy” and an average target price of $77.20.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.